US4364401012 - Common Stock

Overall **HOLX** gets a fundamental rating of **6** out of 10. We evaluated **HOLX** against 187 industry peers in the **Health Care Equipment & Supplies** industry. **HOLX** scores excellent points on both the profitability and health parts. This is a solid base for a good stock. **HOLX** is valued correctly, but it does not seem to be growing.

In the past year **HOLX** had a positive cash flow from operations.

Looking at the **Return On Assets**, with a value of **5.35%**, **HOLX** belongs to the top of the industry, outperforming **84.49%** of the companies in the same industry.

With an excellent **Return On Equity** value of **9.63%**, **HOLX** belongs to the best of the industry, outperforming **85.56%** of the companies in the same industry.

Measured over the past 3 years, the **Average Return On Invested Capital** for **HOLX** is significantly above the industry average of **8.53%**.

The 3 year average ROIC (**16.15%**) for **HOLX** is well above the current ROIC(**8.53%**). The reason for the recent decline needs to be investigated.

Industry Rank | Sector Rank | ||
---|---|---|---|

ROA | 5.35% | ||

ROE | 9.63% | ||

ROIC | 8.53% |

ROA(3y)13.44%

ROA(5y)10.53%

ROE(3y)26.72%

ROE(5y)22.35%

ROIC(3y)16.15%

ROIC(5y)14.15%

In the last couple of years the **Profit Margin** of **HOLX** has declined.

With an excellent **Operating Margin** value of **22.37%**, **HOLX** belongs to the best of the industry, outperforming **95.19%** of the companies in the same industry.

In the last couple of years the **Operating Margin** of **HOLX** has grown nicely.

Industry Rank | Sector Rank | ||
---|---|---|---|

OM | 22.37% | ||

PM (TTM) | 11.78% | ||

GM | 55.12% |

OM growth 3Y-8.49%

OM growth 5Y8.14%

PM growth 3Y-27.37%

PM growth 5YN/A

GM growth 3Y-2.18%

GM growth 5Y1.16%

The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so **HOLX** is still creating some value.

Compared to 1 year ago, **HOLX** has less shares outstanding

An Altman-Z score of **4.35** indicates that **HOLX** is not in any danger for bankruptcy at the moment.

With a decent **Altman-Z score** value of **4.35**, **HOLX** is doing good in the industry, outperforming **72.19%** of the companies in the same industry.

The Debt to FCF ratio of **HOLX** is **2.71**, which is a good value as it means it would take **HOLX**, **2.71** years of fcf income to pay off all of its debts.

Industry Rank | Sector Rank | ||
---|---|---|---|

Debt/Equity | 0.52 | ||

Debt/FCF | 2.71 | ||

Altman-Z | 4.35 |

ROIC/WACC0.94

WACC9.05%

A Current Ratio of **3.97** indicates that **HOLX** has no problem at all paying its short term obligations.

Industry Rank | Sector Rank | ||
---|---|---|---|

Current Ratio | 3.97 | ||

Quick Ratio | 3.29 |

Measured over the past years, **HOLX** shows a small growth in **Revenue**. The Revenue has been growing by **4.61%** on average per year.

EPS 1Y (TTM)-1.79%

EPS 3Y-0.42%

EPS 5Y12.01%

EPS Q2Q%-2.83%

Revenue 1Y (TTM)-2.37%

Revenue growth 3Y2.19%

Revenue growth 5Y4.61%

Sales Q2Q%-0.85%

Based on estimates for the next years, **HOLX** will show a small growth in **Earnings Per Share**. The EPS will grow by **7.31%** on average per year.

The **Revenue** is expected to grow by **4.64%** on average over the next years.

EPS Next Y5.05%

EPS Next 2Y7.12%

EPS Next 3Y8.02%

EPS Next 5Y7.31%

Revenue Next Year0.24%

Revenue Next 2Y2.82%

Revenue Next 3Y3.79%

Revenue Next 5Y4.64%

The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.

A **Price/Earnings** ratio of **20.14** indicates a rather expensive valuation of **HOLX**.

85.56% of the companies in the same industry are more expensive than **HOLX**, based on the **Price/Earnings** ratio.

The average S&P500 **Price/Earnings** ratio is at **28.91**. **HOLX** is valued slightly cheaper when compared to this.

A **Price/Forward Earnings** ratio of **17.02** indicates a rather expensive valuation of **HOLX**.

86.63% of the companies in the same industry are more expensive than **HOLX**, based on the **Price/Forward Earnings** ratio.

Industry Rank | Sector Rank | ||
---|---|---|---|

PE | 20.14 | ||

Fwd PE | 17.02 |

Compared to the rest of the industry, the **Enterprise Value to EBITDA** ratio of **HOLX** indicates a rather cheap valuation: **HOLX** is cheaper than 87.17% of the companies listed in the same industry.

Based on the **Price/Free Cash Flow** ratio, **HOLX** is valued cheaply inside the industry as 91.44% of the companies are valued more expensively.

Industry Rank | Sector Rank | ||
---|---|---|---|

P/FCF | 18.97 | ||

EV/EBITDA | 15.14 |

The high **PEG Ratio(NY)**, which compensates the Price/Earnings for growth, indicates **HOLX** does not grow enough to justify the current Price/Earnings ratio.

The excellent profitability rating of **HOLX** may justify a higher PE ratio.

PEG (NY)3.99

PEG (5Y)1.68

EPS Next 2Y7.12%

EPS Next 3Y8.02%

No dividends for **HOLX**!.

Industry Rank | Sector Rank | ||
---|---|---|---|

Dividend Yield | N/A |

**HOLOGIC INC**

NASDAQ:HOLX (7/12/2024, 10:10:59 AM)

**77.15**

**+0.66 (+0.86%) **

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupHealth Care Equipment & Services

GICS IndustryHealth Care Equipment & Supplies

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap18.01B

Analysts

Price Target

Dividend

Industry Rank | Sector Rank | ||
---|---|---|---|

Dividend Yield | N/A |

Dividend Growth(5Y)

DP

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

Industry Rank | Sector Rank | ||
---|---|---|---|

PE | 20.14 | ||

Fwd PE | 17.02 | ||

P/S | |||

P/FCF | |||

P/OCF | |||

P/B | |||

P/tB | |||

EV/EBITDA |

EPS(TTM)

EY

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)3.99

PEG (5Y)1.68

Profitability

Industry Rank | Sector Rank | ||
---|---|---|---|

ROA | 5.35% | ||

ROE | 9.63% | ||

ROCE | |||

ROIC | |||

ROICexc | |||

ROICexgc | |||

OM | 22.37% | ||

PM (TTM) | 11.78% | ||

GM | 55.12% | ||

FCFM |

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.45

Health

Industry Rank | Sector Rank | ||
---|---|---|---|

Debt/Equity | 0.52 | ||

Debt/FCF | |||

Debt/EBITDA | |||

Cap/Depr | |||

Cap/Sales | |||

Interest Coverage | |||

Cash Conversion | |||

Profit Quality | |||

Current Ratio | 3.97 | ||

Quick Ratio | 3.29 | ||

Altman-Z |

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

High Growth Momentum

Growth

EPS 1Y (TTM)-1.79%

EPS 3Y-0.42%

EPS 5Y

EPS Q2Q%

EPS Next Y5.05%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)-2.37%

Revenue growth 3Y2.19%

Revenue growth 5Y

Sales Q2Q%

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y